Sugi Predict

Sugi Predict / Compounds / SCHEMBL6206910

SCHEMBL6206910

SCHEMBL6206910

N#Cc1c(N)ncc2c1Nc1ccccc1S2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.43
▸ GAA P10253 6/20 0.43
▸ NOX1 Q9Y5S8 5/20 0.43
▸ BCHE P06276 2/20 0.43
▸ ACHE P22303 2/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ CYP1A2 P05177 2/20 0.43
▸ ALOX15 P16050 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ TDP1 Q9NUW8 2/20 0.43
▸ POLB P06746 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ ADORA3 P0DMS8 1/20 0.43
▸ ALOX12 P18054 1/20 0.43
▸ MAOA P21397 1/20 0.43
▸ CNR1 P21554 1/20 0.43
▸ PTGS1 P23219 1/20 0.43
▸ SLC6A2 P23975 1/20 0.43
▸ HTR2C P28335 1/20 0.43
▸ PTGS2 P35354 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6545376 0.70 GAA (0.44) MAPTGAANOX1BCHEACHE
SCHEMBL15909030 0.70 NOX1 (0.44) MAPTGAANOX1BCHEACHE
SCHEMBL31730317 0.69 NOX1 (0.48) MAPTGAANOX1BCHEACHE
SCHEMBL2583563 0.68 NOX1 (0.53) MAPTGAANOX1BCHEACHE
SCHEMBL11448015 0.68 GAA (0.41) MAPTGAANOX1BCHEACHE
Phenothiazine SCHEMBL17006488 0.67 NOX1 (0.94) MAPTGAANOX1BCHEACHE
SCHEMBL8419614 0.67 NOX1 (0.43) MAPTGAANOX1BCHEACHE
SCHEMBL30499564 0.65 NOX1 (0.59) MAPTGAANOX1BCHEACHE
SCHEMBL88106 0.65 NOX1 (0.59) MAPTGAANOX1BCHEACHE
Phenothiazine SCHEMBL1146711 0.65 NOX1 (0.90) MAPTGAANOX1BCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1569645-A2 METHOD OF USING AMINOCYANOPYRIDINE COMPOUNDS AS MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS Pharmacia Corporation (US) 2005-09-07 — — EP claimed
EP-1569942-A2 TRICYCLIC AMINOCYANOPYRIDINE INHIBITORS OF MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 Pharmacia Corporation (US) 2005-09-07 — — EP claimed
WO-2004054504-A2 TRICYCLIC AMINOCYANOPYRIDINE INHIBITORS OF MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 PHARMACIA CORPORATION (US) 2004-07-01 — — WO claimed
WO-2004054505-A2 METHOD OF USING AMINOCYANOPYRIDINE COMPOUNDS AS MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS PHARMACIA CORPORATION (US) 2004-07-01 — — WO claimed
US-20040127511-A1 Tricyclic aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2 PHARMACIA CORPORATION 2004-07-01 — — US claimed
US-20040127519-A1 Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors PHARMACIA CORPORATION 2004-07-01 — — US claimed
EP-1569645-A2 METHOD OF USING AMINOCYANOPYRIDINE COMPOUNDS AS MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS Pharmacia Corporation (US) 2005-09-07 — — EP disclosed
EP-1569942-A2 TRICYCLIC AMINOCYANOPYRIDINE INHIBITORS OF MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 Pharmacia Corporation (US) 2005-09-07 — — EP disclosed
EP-1569938-A1 METHOD OF MAKING TRICYCLIC AMINOCYANOPYRIDINE COMPOUNDS Pharmacia Corporation (US) 2005-09-07 — — EP disclosed
US-6909001-B2 Method of making tricyclic aminocyanopyridine compounds PHARMACIA CORPORATION (US) 2005-06-21 — — US disclosed
US-20040127714-A1 Method of making tricyclic aminocyanopyridine compounds PHARMACIA CORPORATION 2004-07-01 — — US disclosed
WO-2004055019-A1 METHOD OF MAKING TRICYCLIC AMINOCYANOPYRIDINE COMPOUNDS PHARMACIA CORPORATION (US) 2004-07-01 — — WO disclosed
WO-2004054504-A2 TRICYCLIC AMINOCYANOPYRIDINE INHIBITORS OF MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 PHARMACIA CORPORATION (US) 2004-07-01 — — WO disclosed
WO-2004054505-A2 METHOD OF USING AMINOCYANOPYRIDINE COMPOUNDS AS MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS PHARMACIA CORPORATION (US) 2004-07-01 — — WO disclosed
US-20040127511-A1 Tricyclic aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2 PHARMACIA CORPORATION 2004-07-01 — — US disclosed
US-20040127519-A1 Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors PHARMACIA CORPORATION 2004-07-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127519-A1 Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors MAPKAPK2, MAP2K2, MAP3K2 MAPT 2094/4885GAA 2654/4885NOX1 846/4885
US-20040127714-A1 Method of making tricyclic aminocyanopyridine compounds MAP4K2, PACSIN2, MAPKAPK2 MAPT 2172/4885GAA 4125/4885NOX1 2078/4885
US-20040127511-A1 Tricyclic aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2 MAPKAPK2, MAP4K2, MAP3K2 MAPT 1860/4885GAA 2805/4885NOX1 2308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.